The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib

Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis. Here, we investigated the predictive values of the HTATIP2 level and microvessel density (MVD) with or without sorafenib administration for HCC. Three independent cohorts were included. Using tissue microarray, we assessed the relationship between HTATIP2 expression/MVD and overall survival. The results showed that high HTATIP2 expression and a low MVD value were independent protective prognostic factors after curative HCC resection (297 cases/cohort 1); however, both parameters were converted to independent negative prognostic indicators for patients with postsurgical sorafenib treatment (69/143 cases/cohort 2; P<0.05 for all). This same relationship was observed in patients that received sorafenib treatment for advanced HCC (83 cases/cohort 3; efficacy measures and survival analyses, P<0.05 for all). Moreover, the combination of HTATIP2 and MVD had better power to predict patient death and disease recurrence (P<0.001 for both). We conclude that the combination of HTATIP2 and MVD predicts the converse survival of HCC with or without sorafenib intervention. Our findings can assist in the selection of candidates for personalized treatment with sorafenib.

[1]  Xian-gui Hu,et al.  Decreased TIP30 expression predicts poor prognosis in pancreatic cancer patients , 2014, International journal of cancer.

[2]  Zhao-You Tang,et al.  Intratumoral α-SMA Enhances the Prognostic Potency of CD34 Associated with Maintenance of Microvessel Integrity in Hepatocellular Carcinoma and Pancreatic Cancer , 2013, PloS one.

[3]  Zhao-You Tang,et al.  Aspirin Minimized the Pro-Metastasis Effect of Sorafenib and Improved Survival by Up-Regulating HTATIP2 in Hepatocellular Carcinoma , 2013, PloS one.

[4]  Chengliang Zhang,et al.  TIP30 loss enhances cytoplasmic and nuclear EGFR signaling and promotes lung adenocarcinogenesis in mice , 2012, Oncogene.

[5]  Zhao-You Tang,et al.  Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice. , 2012, Gastroenterology.

[6]  J. Bruix,et al.  Hepatocellular carcinoma , 2012, The Lancet.

[7]  Zainab N. Khan,et al.  Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. , 2012, Cancer cell.

[8]  D. Xie,et al.  Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model , 2011, Hepatology.

[9]  Chih-Hung Hsu,et al.  Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy. , 2011, The oncologist.

[10]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[11]  M. Grandoch,et al.  Stimulatory effects of the multi‐kinase inhibitor sorafenib on human bladder cancer cells , 2010, British journal of pharmacology.

[12]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. , 2010, The oncologist.

[13]  Zhao-You Tang,et al.  Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects , 2010, Clinical Cancer Research.

[14]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[15]  R. Kerbel,et al.  Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy , 2009, Clinical Cancer Research.

[16]  Sonja Loges,et al.  Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. , 2009, Cancer cell.

[17]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[18]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[19]  D. V. van Spronsen,et al.  The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases , 2009, Acta oncologica.

[20]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[21]  T. Sauerbruch,et al.  [Sorafenib in advanced hepatocellular carcinoma]. , 2009, Der Internist.

[22]  W. Cong,et al.  Thirty‐kilodalton Tat‐interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma , 2008, Hepatology.

[23]  Zhao-You Tang,et al.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Jian Zhao,et al.  TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. , 2008, Cancer research.

[25]  Q. Ye,et al.  Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. , 2007, Journal of hepatology.

[26]  Zhao-You Tang,et al.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jian Zhao,et al.  TIP30/CC3 expression in breast carcinoma: relation to metastasis, clinicopathologic parameters, and P53 expression. , 2007, Human pathology.

[28]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[29]  Jian Zhao,et al.  TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5‐FU , 2006, Hepatology.

[30]  R. Roeder,et al.  TIP30 deficiency increases susceptibility to tumorigenesis. , 2003, Cancer research.

[31]  S. Fan,et al.  Tumor microvessel density as a predictor of recurrence after resection of hepatocellular carcinoma: a prospective study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Shtivelman,et al.  Metastasis suppressor CC3 inhibits angiogenic properties of tumor cells in vitro , 2001, Oncogene.

[33]  W. Stetler-Stevenson,et al.  Increased expression of tissue inhibitor of metalloproteinases type 1 (TIMP‐1) in a more tumourigenic colon cancer cell line , 2000, The Journal of pathology.

[34]  Zeng-chen Ma,et al.  Microvessel density of hepatocellular carcinoma: its relationship with prognosis , 1999, Journal of Cancer Research and Clinical Oncology.

[35]  A. Thor,et al.  Systemic Gene Delivery Expands the Repertoire of Effective Antiangiogenic Agents* , 1999, The Journal of Biological Chemistry.

[36]  E. Shtivelman.  A link between metastasis and resistance to apoptosis of variant small cell lung carcinoma , 1997, Oncogene.

[37]  W. Travis,et al.  A Report of Three Cases , 1986 .